RANDOX

TYPE 1 DIABETES (T1D)

SNP Array

Discrimination between T1D and other non-autoimmune Diabetes

Using patented **Biochip array technology**, Randox have developed a Type 1 Diabetes (T1D) Genetic Risk Score (GRS) Array.

Using a combination of 10 SNPs from both HLA and non-HLA regions commonly associated with T1D, a GRS can be calculated that, when used in combination with other risk factors, can accurately aid in the discrimination of T1D from other non-autoimmune Diabetes.

TEST Benefits

Accurate discrimination between T1D and other non-autoimmune Diabetes preventing misdiagnosis.

Provides rapid genetic risk assessment for T1D.

Ability to genotype 10 SNPs associated with T1D.

Can aid accurate diagnosis to ensure proper patient care management and prevention of life-threatening complications.

SNP Targets Detected

SNP	GENES
rs2187668 rs7454108	DR3/DR4-DQ8 DR3/DR3 DR4-DQ8/DR4-DQ8 DR4-DQ8/X DR3/X
rs1264813	HLA_A_24
rs2395029	HLA_B_5701
rs3129889	HLA_DRB1_15
rs2476601	PTPN22
rs689	INS
rs12722495	IL2RA
rs2292239	ERBB3
rs10509540	C10orf59

Meet the Evidence Investigator

- Renowned for its versatility, robustness and effective reporting methods, the Evidence Investigator is a semi-automated, benchtop platform that offers efficient and comprehensive testing without compromising accuracy.

- Using chemiluminescent as a measurement principle, the Evidence Investigator consistently delivers accurate results.

- All data is analysed on-board, removing issues related to human error and result manipulation.

Meet the Biochip

Biochip technology multiplexing allows up to 49 Discrete Test Regions (DTR) per chip, enabling 44 simultaneous tests. The Evidence Investigator can host up to 6 biochips per carrier, enhancing throughput. Protein and DNA-based biochips consolidate tests, improving efficiency.